[Tamoxifen in the adjuvant setting for breast cancer: Reflexions about the risk of uterine carcinosarcoma].
A descriptive analysis of available data on reported cases of uterine carcinosarcomas associated with tamoxifen therapy is undertaken. The role of aromatase inhibitors as alternative to tamoxifen therapy in the adjuvant setting of breast cancer is discussed. The eventual implications of the presumed association of uterine carcinosarcoma and tamoxifen therapy on the choice of the therapeutic agent in the adjuvant setting of hormone-sensitive breast cancer are discussed.
Leung
F
F
Service de gynécologie-obstétrique, hôpital Saint-Jacques, CHU de Besançon, 25030 Besançon, France. Fabrice_Leung@yahoo.com
Terzibachian
J-J
JJ
Govyadovskiy
A
A
Bourtembourg
A
A
Maillet
R
R
Riethmuller
D
D
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D002296:Carcinosarcoma / Q000188:drug therapy*; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017698:Postmenopause; D011379:Prognosis; D012307:Risk Factors; D013629:Tamoxifen / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004965:Estrogen Antagonists; D013629:Tamoxifen